Ethambutol
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MYAMBUTOL | — | 1967-11-06 | fda.gov ↗ |
Trials 54 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 86 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07058090 Comparator | Jul → Dec 2025 overdue | drug-induced liver injury, tuberculosis | Liaquat National Hospital & Medical College | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT01169038 Comparator | Jul → Nov 2010 | pulmonary sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00004736 Background | — | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03678688 Comparator | Oct 2018 → Feb 2022 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 241 trials | ||||||
| Phase 2 | NCT07656012 Background | Sep 2026 → Sep 2030 expected | tuberculosis | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07467252 Comparator | Sep 2026 → Dec 2027 expected | pulmonary tuberculosis | Ministry of Health, Saudi Arabia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07595042 Comparator | Jul 2026 → Jun 2029 expected | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07350174 Comparator | Mar 2026 → Mar 2028 expected | meningeal tuberculosis | BioVersys AG | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07303699 Background | Jan 2026 → Mar 2027 expected | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07073638 Background | Oct 2025 → Sep 2026 expected | pulmonary tuberculosis | Thirty Respiratory Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06446245 Background | Aug 2025 → Nov 2027 expected | meningeal tuberculosis | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT07129629 Comparator | Aug 2025 → Dec 2026 expected | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06917495 Comparator | Apr 2025 → Dec 2027 expected | tuberculosis, spinal | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06192160 Comparator | Mar 2025 → Nov 2026 expected | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT06585020 Comparator | Oct 2024 → Aug 2026 overdue | Mycobacterium xenopi infection, lung disorder | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 2 | NCT06114628 Comparator | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT06199921 Comparator | Jan 2024 → Mar 2026 overdue | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05383742 Comparator | Dec 2023 → Apr 2028 expected | meningeal tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT05556746 Comparator | Nov 2023 → Jun 2025 overdue | HIV infectious disease, pulmonary tuberculosis | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06058299 Comparator | Oct 2023 → Dec 2024 overdue | pulmonary tuberculosis | Global Alliance for TB Drug Development | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06224036 Comparator | Oct 2023 → Mar 2024 | drug-resistant tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05534750 Comparator | Apr 2023 → Apr 2026 overdue | multidrug-resistant tuberculosis | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT04694586 Background | Nov 2022 → May 2024 | pulmonary tuberculosis | University Hospital, Linkoeping | Suspended | No outcome recorded |
| Phase 2 | NCT04930744 Background | Aug 2021 → Apr 2025 | coinfection, pulmonary tuberculosis | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT04553406 Comparator | Dec 2020 → Jan 2021 | Mycobacterium avium complex disease, pulmonary non-tuberculous mycobacterial infection | Spero Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04504851 Background | Aug 2020 → Mar 2021 | pulmonary tuberculosis | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT04176250 Comparator | Jan 2020 → Oct 2022 | pulmonary tuberculosis | Gates Medical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03927313 Background | Jun 2019 → Mar 2021 | HIV infectious disease, meningeal tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 2 | NCT03563599 Comparator | Jul 2018 → Sep 2019 | tuberculosis | Qurient Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02836483 Comparator | Dec 2016 → Jul 2019 | pulmonary tuberculosis | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03281226 Comparator | Dec 2016 → Jun 2019 | AIDS, pulmonary tuberculosis | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Unknown | No outcome recorded |
| Phase 2 | NCT01589497 Comparator | Jun 2015 → Jan 2016 | tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02256696 Comparator | Apr 2015 → May 2022 | pulmonary tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2 | NCT02279875 Comparator | Nov 2014 → Nov 2016 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT02193776 Comparator | Oct 2014 → Feb 2016 | tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT02024555 Comparator | Mar 2014 → Apr 2019 | sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT01994460 Comparator | Jan 2014 → Dec 2015 | pulmonary tuberculosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01601626 Background | Jul 2013 → Jan 2017 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | No outcome recorded |
| Phase 2 | NCT02121314 Comparator | Jul 2013 → Apr 2014 | tuberculosis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT01516203 Comparator | Dec 2012 → Dec 2013 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01225640 Comparator | Aug → Dec 2011 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01215851 Comparator | Oct 2010 → May 2011 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT00728507 Comparator | Nov 2009 → Apr 2013 | tuberculosis | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT00144417 Background | Feb 2006 → Jun 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT05766267 Comparator | Nov 2023 → Dec 2026 expected | pulmonary tuberculosis | Centers for Disease Control and Prevention | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04630145 Background | Jan 2021 → Nov 2024 | Mycobacterium avium complex disease | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2/3 | NCT03672630 Comparator | Feb 2019 → Jan 2026 | Mycobacterium avium complex disease, pulmonary non-tuberculous mycobacterial infection | Kevin Winthrop | Completed | No outcome recorded |
| Phase 2/3 | NCT03338621 Comparator | Jul 2018 → Jul 2021 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2/3 | NCT02169882 Background | Dec 2014 → Nov 2016 | meningeal tuberculosis | Padjadjaran University | Completed | No outcome recorded |
| Phase 2/3 | NCT02467608 Background | Dec 2012 → Jan 2019 | pulmonary tuberculosis | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT00495326 Background | Dec 2007 → Apr 2011 | AIDS, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT07076225 Comparator | Jul 2025 → Jan 2030 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06905522 Comparator | Jun 2025 → Jan 2029 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06253715 Comparator | Jan 2025 → Sep 2027 expected | lymph node tuberculosis, pulmonary tuberculosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT06081361 Comparator | Dec 2023 → Oct 2026 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05454345 Comparator | Oct 2022 → Jun 2025 | pulmonary tuberculosis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04951986 Background | Aug 2021 → Dec 2025 overdue | HIV infectious disease, tuberculosis | University of Cape Town | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04677569 Background | Apr 2021 → Nov 2025 | pulmonary non-tuberculous mycobacterial infection | Insmed Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT04260477 Comparator | Mar 2021 → Jun 2025 overdue | multidrug-resistant tuberculosis, pulmonary tuberculosis | Institute of Tropical Medicine, Belgium | Recruiting | No outcome recorded |
| Phase 3 | NCT04145258 Background | Feb 2021 → Sep 2026 expected | meningeal tuberculosis | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 3 | NCT04677543 Comparator | Dec 2020 → May 2023 | Mycobacterium avium complex disease | Insmed Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT04485156 Comparator | Sep 2020 → Aug 2025 overdue | pulmonary tuberculosis | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04062201 Comparator | Aug 2019 → Apr 2024 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Wits Health Consortium (Pty) Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03236987 Background | Feb 2018 → Feb 2028 expected | Mycobacterium avium complex disease, respiratory tract infectious disorder | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT02581527 Background | Feb 2017 → Jan 2022 | pulmonary tuberculosis | St George's, University of London | Completed | No outcome recorded |
| Phase 3 | NCT02342886 Comparator | Feb 2015 → Jan 2018 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 3 | NCT02153528 Background | Nov 2014 → Aug 2017 | pulmonary tuberculosis | Damien Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00698334 Comparator | Apr 2006 → Sep 2010 | AIDS, tuberculosis | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00001047 Background | ? → Aug 1996 | HIV infectious disease, Mycobacterium avium complex disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00002101 Background | — | HIV infectious disease, Mycobacterium avium complex disease | Pharmacia | Completed | No outcome recorded |
| Phase 3 | NCT00002140 Background | — | HIV infectious disease, Mycobacterium avium complex disease | Pfizer | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT07084402 Background | Jul 2025 → Jul 2027 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT07213765 Comparator | Jul 2025 → Sep 2028 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT06403943 Background | May 2023 → Oct 2026 expected | pulmonary tuberculosis | Beijing Chest Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04921943 Comparator | May 2021 → Dec 2025 overdue | pulmonary non-tuberculous mycobacterial infection | Oregon Health and Science University | Recruiting | No outcome recorded |
| Phase 4 | NCT03867136 Comparator | Jun 2020 → Aug 2024 | multidrug-resistant tuberculosis | Huashan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03561753 Comparator | Dec 2017 → Dec 2019 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 4 | NCT02231229 Comparator | Jul 2014 → Jul 2018 | tuberculosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00367913 Background | Mar 1995 → Sep 2004 | lung disorder | British Thoracic Society | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07608172 Comparator | May 2026 → Jun 2028 expected | pulmonary tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT07585461 Comparator | Apr 2026 → Dec 2028 expected | AIDS-related disorder, Mycobacterium avium complex disease | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT04187469 Comparator | Mar 2020 → Feb 2023 | pulmonary tuberculosis | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT02554318 Background | Nov 2013 → Feb 2015 | pulmonary tuberculosis | University of Giessen | Completed | No outcome recorded |
| — | NCT01677871 Comparator | Sep 2012 → Sep 2014 | tuberculosis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT01344148 Background | Feb 2009 → Jun 2011 | AIDS | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
Evidence & citations 30 cited values
Every value below carries the sentence it was read from. 143 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ethambutol | “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗134“INTERVENTIONS: Patients were randomized to receive daily treatment with 4 drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) given as an FDC (n = 798 patients) or...” PMID 21486974 ↗ Apr 2011 “FDC intensive phase containing 150 mg of rifampicin, 75 mg of isoniazid not 300mg, 400 mg of pyrazinamide, and 275 mg of ethambutol, while FDC continuation phase containing...” NCT05005637 ↗ “The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid” NCT03830671 ↗ “The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.” NCT03561753 ↗ “Current guidelines recommend a macrolide-based triple therapy consisting of a macrolide (azithromycin or clarithromycin), ethambutol, and a rifamycin (typically rifabutin).” NCT07585461 ↗ “This study aimed to quantify the influence of food on the pharmacokinetics of isoniazid, rifampicin, ethambutol and pyrazinamide in TB patients starting anti-TB treatment.” PMID 26661397 ↗ Dec 2015 “SOC plus 6 months of tuberculosis treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, plus isoniazid and rifampicin for 4 subsequent months)” PMID 42468541 ↗ Jul 2026 “using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]).” NCT02371681 ↗ “Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained” NCT02153528 ↗ “Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight)” NCT03281226 ↗ “including rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day” NCT06446245 ↗ “Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days” NCT04176250 ↗ “Two months of isoniazid (H), ethambutol (E), rifampicin (R) and Pyrazinamide (Z) followed by HR(E) for another two months” NCT06727864 ↗ “Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months” NCT01677871 ↗ “Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)” NCT01225640 ↗ “10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.” NCT03927313 ↗ “Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.” NCT04044001 ↗ “isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin” NCT04145258 ↗ “2 months of isoniazid, rifampin, pyrazinamide, and ethambutol followed by 4 months of isoniazid and rifampin” NCT07608172 ↗ “Isoniazid (5 mg/kg/day); Rifampicin (10 mg/kg/day); Pyrazinamide (30 mg/kg/day); Ethambutol (20 mg/kg/day).” NCT07350174 ↗ “isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets” NCT03338621 ↗ “or an active control of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) or linezolid 600 mg BID.” PMID 34871098 ↗ Dec 2021 “Arm 1 participants will receive high-dose rifampicin plus ethambutol (EMB) at standard doses for 8 weeks.” NCT02958709 ↗ “Isoniazid (H) + rifampicin (R) + pyrazinamide (Z), ethambutol (E) for 8 weeks followed by HR for 18 weeks” NCT06058299 ↗ “ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, \>71kg 1375mg daily; All treatment is taken orally.” NCT05401071 ↗ “Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol.” NCT03678688 ↗ “Anti-Tb Therapy: 2HREZ-4HRifb(H:Isoniazid，R:Rifampicin，E:Ethambutol，Z：pyrazinamide，Rifb:Rifabutin)” NCT01344148 ↗ “standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E) 15-20 mg/kg daily for 8 weeks” NCT04738812 ↗ “each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol” NCT01215851 ↗ “isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets” NCT04694586 ↗ “isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)” NCT06041919 ↗ “ethambutol (0.75g for weight 50kg and below, 1.0g for weight 50kg and above)” NCT06403943 ↗ “such as linezolid, clofazimine or ethambutol based on the DST results” NCT03604848 ↗ “other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin” NCT02169882 ↗ “Isoniazid (H) , Rifampicin (R), Pyrazinamide (Z) and Ethambutol (E)” NCT06153069 ↗ “moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide” PMID 29519716 ↗ Mar 2018 “RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)” NCT03563599 ↗ “Standard treatment = Rifampicin, ethambutol and clarithromycin” NCT06585020 ↗ “pyrazinamide, ethambutol, levofloxacin, moxifloxacin” NCT03237182 ↗ “Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily” NCT03867136 ↗ “Ethambutol; isoniazid; rifampicin; pyrazinamide” NCT04260477 ↗ “Ethambutol 15-20mg / kg / day for 7 days” NCT05534750 ↗ “ethambutol [E]: 800-1600mg daily” NCT02467608 ↗ “ethambutol (EMB or E)” NCT02231229 ↗ “Ethambutol=Myambutol” NCT01074554 ↗ |
| Known as | CL 40881 | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Dadibutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Dexambutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | E-ethambutol | “The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid” NCT03830671 ↗ |
| Known as | Ebutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | EMB | “Arm 1 participants will receive high-dose rifampicin plus ethambutol (EMB) at standard doses for 8 weeks.” NCT02958709 ↗5“regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)” PMID 24903795 ↗ May 2014 “ethambutol (EMB) 20 mg/kg” NCT05383742 ↗ “ethambutol (EMB \[E\])” NCT02371681 ↗ “ethambutol (EMB or E)” NCT02231229 ↗ “ethambutol [EB, EMB]” NCT02365623 ↗ |
| Known as | Etambutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Etapiam | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Ethambutol (E) | “Ethambutol (E)” NCT07656012 ↗ |
| Known as | Ethambutol dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Ethambutol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | ETHAMBUTOL HYDROBROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Ethambutol hydrochloride | “This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol...” NCT06224036 ↗4“Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or” NCT04553406 ↗ |
| Known as | ethambutol tablets | “ethambutol tablets” NCT02331823 ↗ |
| Known as | Ethambutol=Myambutol | “Ethambutol=Myambutol” NCT01074554 ↗ |
| Known as | Ethambutoli hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Etibi | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Myambutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Mycobutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Mynah 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Mynah 250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Mynah 300 | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Mynah 365 | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | NSC-757022 | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Servambutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Tambutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Known as | Tibutol | ChEMBL registry synonym — accepted as the source's own label CHEMBL44884 ↗ |
| Modality | Small molecule | “two molecules, rifampin and ethambutol, in combination with a third randomized molecule” NCT03236987 ↗ |
| Route | Oral | “ciprofloxacin, clofazimine, ethambutol, and rifampin (all taken orally)” NCT00000641 ↗ |